Real-World Safety and Clinical Response of Janus Kinase Inhibitor Upadacitinib in the Treatment of Hidradenitis Suppurativa: A Retrospective Cohort Study
Published: 15 September 2022| Version 2 | DOI: 10.17632/fjv74v2w65.2
Contributor:
John Frew
Description
Real-World Safety and Clinical Response of Janus Kinase Inhibitor Upadacitinib in the Treatment of Hidradenitis Suppurativa: A Retrospective Cohort Study - JAAD 2022
Files
Categories
Dermatology, Hidradenitis Suppurativa, Janus Kinase